Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT: Mitomycin C PIPAC - FOLFIRI Combination for Unresectable Appendiceal or Colorectal Peritoneal Metastases
NCT07271355Phase 3Recruiting
- Sponsor
- City of Hope
- Start
- Oct 2026
- Primary completion
- Feb 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mitomycin c in appendiceal cancer, colorectal cancer (CRC), Peritoneal metastases, sponsored by City of Hope. Started Oct 2026; status: recruiting.
02
Drugs
mitomycin c
03
Conditions
appendiceal cancercolorectal cancer (CRC)Peritoneal metastases
Beyond the preview
Go deeper on NCT07271355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07271355.